Transcytosis is the process by which a cell picks up cargo on one side, ferries it through its interior inside a membrane-bound bubble, and releases it on the opposite side. It is the body’s workaround for moving large molecules across cell barriers that would otherwise be impassable. The process operates in blood vessels, the gut lining, the placenta, and the brain’s famously tight vascular walls, serving purposes that range from immune defense to fetal nutrition. It has also become one of the most actively pursued routes for getting drugs into the brain.
How Cargo Crosses a Cell
Cells that form barriers, whether lining a blood vessel or the intestinal wall, are sealed together by tight junctions that prevent most large molecules from slipping between them. Transcytosis solves this by taking molecules through the cell rather than around it. A receptor on one surface of the cell grabs a specific molecule, pulls it inward inside a small vesicle, and the cell’s internal machinery moves that vesicle across the cytoplasm to the opposite surface, where the cargo is expelled.1PubMed. Transcellular vesicular transport in epithelial and endothelial cells: Challenges and opportunities This sequence of uptake, transit, and release allows molecules like antibodies, hormones, and nutrients to cross intact tissue layers without the barrier ever being breached.
The transit step is not passive. Once a vesicle is pinched off from the cell membrane, motor proteins haul it along tracks made of microtubules and actin filaments. Blocking those tracks or disabling the motors stalls transcytosis.2PubMed. Endocytic traffic in polarized epithelial cells: role of the actin and microtubule cytoskeleton Kinesin pulls vesicles in one direction along microtubules, dynein pulls them in the other, and myosin motors handle shorter-range movements on actin. This gives the cell fine control over where things end up. Beyond simple transport, transcytosis also redistributes membrane proteins and lipids from one region of the cell surface to another, which helps maintain the distinct identity of each face of the cell.
Caveolae and Blood Vessel Walls
Blood vessel walls are lined with endothelial cells, and one of the main vehicles for transcytosis in these cells is the caveola, a tiny flask-shaped dimple in the cell membrane roughly 50 to 100 nanometers across.3Cell and Tissue Research. Caveolae and transcytosis in endothelial cells: Role in atherosclerosis Caveolae pinch off from one surface, carry their cargo across the cell, and fuse with the opposite membrane. They possess the molecular machinery for membrane fusion, detachment, and directed movement, and they handle a surprising roster of large molecules: albumin, low-density lipoproteins, insulin, and various enzymes all travel this way.4PubMed. Transcytosis of plasma macromolecules in endothelial cells: a cell biological survey
This transport is not always benign. In atherosclerosis, caveolae-mediated transcytosis of LDL cholesterol across the arterial endothelium is believed to contribute to plaque formation. The same machinery that helps deliver nutrients to tissues also deposits lipoproteins in the vessel wall, where they can accumulate and trigger inflammation. Caveolin-1, the main structural protein of caveolae, has become a focus of research into how endothelial transcytosis contributes to cardiovascular disease.
Antibody Shuttling in the Gut
Your gut faces a constant onslaught of microbes, and one of its primary defenses is a steady supply of secretory antibodies, mainly IgA, delivered to the mucus layer via transcytosis. Immune cells in the tissue beneath the gut lining produce IgA, which then binds to a receptor called the polymeric immunoglobulin receptor (pIgR) on the inner face of the epithelial cell. The cell transcytoses the IgA to its outer, lumen-facing surface and clips it free, releasing it into the mucus where it can neutralize bacteria and toxins before they ever touch the epithelium.5PubMed Central. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis IgM, a larger antibody, uses the same receptor and pathway.
Recent work has uncovered an additional twist. A subset of IgA-producing plasma cells in the intestine express an integrin that lets them physically dock with the epithelial cell and hand their antibody cargo directly to pIgR, rather than simply releasing it into the surrounding tissue and hoping the receptor picks it up.6Mucosal Immunology. An integrin αEβ7-dependent mechanism of IgA transcytosis requires direct plasma cell contact with intestinal epithelium This direct handoff appears to be important for maintaining adequate levels of secretory IgA in the gut lumen. It suggests that transcytosis is not always a one-cell affair; the upstream supply chain matters, too.
Transcytosis in the gut also runs in the opposite direction, from the lumen inward. Specialized epithelial cells called microfold cells, or M cells, sit above clusters of immune tissue known as Peyer’s patches in the small intestine. M cells sample bacteria, food particles, and other antigens from the gut lumen and transcytose them to immune cells waiting below, where dendritic cells capture and present them to trigger appropriate immune responses.7PubMed Central. The Roles of Peyer’s Patches and Microfold Cells in the Gut Immune System: Relevance to Autoimmune Diseases8PubMed Central. Peyer’s patches: organizing B-cell responses at the intestinal frontier This inward transcytosis is how the immune system monitors what is happening in the gut without tearing open the barrier.
Protecting Newborns Before and After Birth
Fetuses and newborns have immature immune systems and depend heavily on antibodies borrowed from their mother. Getting those antibodies across tissue barriers is a transcytosis job. In the placenta, the syncytiotrophoblast, a continuous layer of fused cells separating maternal and fetal blood, uses the neonatal Fc receptor (FcRn) to grab maternal IgG and transcytose it into the fetal circulation.9PubMed Central. Factors Affecting the FcRn-Mediated Transplacental Transfer of Antibodies and Implications for Vaccination in Pregnancy This is the reason that vaccinating pregnant women can protect their babies during the first months of life: the vaccine-induced IgG is actively transported to the fetus via this receptor.
The same receptor continues its work after birth. In the neonatal gut, FcRn transcytoses IgG from breast milk across the intestinal epithelium, delivering maternal antibodies into the infant’s bloodstream. Interestingly, FcRn-mediated transport is bidirectional: the receptor can also carry IgG from the bloodstream back into the gut lumen, where it can bind antigens and then return them across the barrier for processing by immune cells.10JCI Insight. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line11PubMed. IgG transport across mucosal barriers by neonatal Fc receptor for IgG and mucosal immunity FcRn does not just deliver antibodies; it helps maintain their blood levels throughout life by rescuing IgG from degradation inside cells and recycling it back into circulation.
The placenta also transcytoses iron, lipoproteins, and various growth factors needed for fetal development, each using its own receptor and vesicle pathway.12PubMed. Endocytic and transcytotic processes in villous syncytiotrophoblast: role in nutrient transport to the human fetus This selectivity is key: the placenta is not passively leaky. It chooses what crosses, and transcytosis is the gatekeeper mechanism.
The Blood-Brain Barrier
The brain’s blood vessels are sealed so tightly that almost nothing larger than a small molecule gets through on its own. This blood-brain barrier protects the brain from toxins and pathogens, but it also makes delivering drugs to the brain extraordinarily difficult. Transcytosis is one of the few routes available for large molecules to cross this barrier, and it operates through at least two broad mechanisms.
The first is receptor-mediated transcytosis, in which a molecule binds to a specific receptor on the blood-facing side of the endothelial cell and is shuttled across. The transferrin receptor, which normally imports iron into the brain, is the most studied target. Researchers have found that nanoparticles decorated with transferrin can ride this receptor across the barrier and reach the brain tissue on the other side.13PubMed Central. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor A critical insight, however, is that binding too tightly to the receptor is counterproductive. Nanoparticles that grip the transferrin receptor strongly tend to get stuck on the blood-side surface of the cell, whereas those with lower binding strength can attach, cross, and then release on the brain side.14PubMed Central. Blood-Brain Barrier Transport of Transferrin Receptor-Targeted Nanoparticles This “grab gently, let go easily” principle has reshaped how drug-delivery researchers design brain-targeting molecules.
The second broad mechanism is adsorptive transcytosis, which relies on electrical charge rather than a specific receptor. Positively charged molecules are attracted to the negatively charged surface of brain endothelial cells, triggering uptake and transport. In lab models, chemically modified albumin carrying a positive charge crossed endothelial cell layers at about seven times the rate of normal albumin.15PubMed. Permeability and mechanism of albumin, cationized albumin, and glycosylated albumin transcellular transport across monolayers of cultured bovine brain capillary endothelial cells Adsorptive transcytosis is less selective than receptor-mediated transport, but it offers a way to move a broader range of cargo into the brain.16PubMed Central. CNS delivery via adsorptive transcytosis
When Pathogens Hijack the Process
Transcytosis evolved to move the body’s own molecules, but pathogens have learned to exploit it. Many bacteria and toxins that infect through mucosal surfaces use transcytosis to cross epithelial barriers without disrupting them, slipping through quietly rather than punching holes.17PubMed Central. Targeting the Mucosal Barrier: How Pathogens Modulate the Cellular Polarity Network
Botulinum toxin is a striking example. Despite being one of the most lethal substances known by weight, it is primarily acquired by eating contaminated food. For the toxin to cause damage, it must get from the gut lumen into the bloodstream, and it does so by hijacking receptor-mediated transcytosis in intestinal epithelial cells. Lab studies show that botulinum toxin A crosses intestinal cell layers within 30 to 60 minutes via a saturable, temperature-dependent pathway, hallmarks of active receptor-mediated transport rather than passive leakage.18PubMed. Receptor-mediated transcytosis of botulinum neurotoxin A through intestinal cell monolayers Visualization studies have tracked fluorescently labeled toxin as it binds, gets internalized, spreads across the cell, and exits on the basolateral side in as little as five minutes, with the process largely complete within 20 to 30 minutes.19PubMed. Visualization of binding and transcytosis of botulinum toxin by human intestinal epithelial cells
Bacteria can also ride the transcytosis machinery. Neisseria gonorrhoeae, the bacterium responsible for gonorrhea, traverses polarized epithelial cells using the host’s own microtubule and actin motor systems. Blocking kinesin or myosin motors with specific antibodies significantly reduces the bacteria’s ability to cross the cell layer, confirming that the pathogen is co-opting the cell’s transport infrastructure rather than simply boring through.20PubMed. Cytoskeleton and motor proteins are required for the transcytosis of Neisseria gonorrhoeae through polarized epithelial cells Understanding these hijacking strategies is relevant for vaccine and barrier-protection research: if you know how a pathogen crosses, you can start thinking about how to block that crossing.
Clearing Amyloid from the Brain
Transcytosis is not only a way into the brain; it is also a way out. One of the hallmarks of Alzheimer’s disease is the accumulation of amyloid-beta peptide in brain tissue, and the primary route for clearing that peptide is transcytosis across the blood-brain barrier in the outward direction. A receptor called LRP1, concentrated on the brain-facing side of the endothelium, grabs amyloid-beta and shuttles it into the bloodstream for disposal.21PubMed Central. Clearance of amyloid-β peptide across the blood-brain barrier: Implication for therapies in Alzheimer’s disease When researchers knocked out LRP1 in brain endothelial cells, transcytosis of amyloid-beta dropped by about half, and the receptor’s contribution grew even more pronounced at higher amyloid concentrations.22JCI Insight. Endothelial LRP1 transports amyloid-β1–42 across the blood-brain barrier
A separate protein called PICALM also plays a central role in this clearance pathway. PICALM levels are reduced in endothelial cells affected by Alzheimer’s disease, and that reduction tracks with impaired amyloid-beta clearance. Restoring PICALM expression in those cells reversed the clearance deficit in lab models.23Nature Neuroscience. Central role for PICALM in amyloid-β blood-brain barrier transcytosis and clearance These findings have fueled interest in boosting outward transcytosis as a therapeutic strategy, on the logic that if the brain’s garbage removal system can be repaired or enhanced, amyloid accumulation might slow.
Designing Drugs That Ride the System
Because the blood-brain barrier blocks nearly all conventional drugs, researchers have spent decades trying to engineer particles that can exploit transcytosis to sneak therapeutics through. The basic strategy is to coat a nanoparticle with a molecule that a receptor on the brain endothelium already recognizes, then let the cell’s own transport machinery carry the particle across.
Transferrin-coated gold nanoparticles have been shown to reach brain tissue in mice after being injected into the bloodstream. Particles of both 45 and 80 nanometers in diameter made it through, but accumulation on the brain side depended on how much transferrin was attached. More transferrin meant tighter binding to the receptor, which paradoxically meant the particle stayed glued to the blood-side surface instead of completing the trip.24PubMed Central. Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor This avidity-tuning problem, getting the binding strength into a sweet spot, is one of the central engineering challenges in the field.
The transferrin receptor is not the only doorway being targeted. Lactoferrin, a protein found in milk, binds its own receptor on brain endothelial cells. Iron oxide nanoparticles coated with lactoferrin showed enhanced ability to cross the blood-brain barrier compared to uncoated particles in both cell-culture and animal experiments.25PubMed. Receptor-mediated delivery of magnetic nanoparticles across the blood-brain barrier The magnetic properties of these iron oxide particles raise the additional possibility of using them for brain imaging, making them dual-purpose diagnostic and therapeutic tools.26PubMed Central. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis
At the molecular level, researchers have begun to identify the internal sorting machinery that determines whether a vesicle carrying cargo across the cell actually completes the journey or gets diverted to a recycling pathway that sends the cargo back where it started. A protein called Rab17 promotes the formation of tubular sorting structures inside brain endothelial cells, and overexpressing Rab17 significantly increased transcytosis of antibody fragments across those cells in vitro.27Cell Reports. Sorting Tubules Regulate Receptor-Mediated Transcytosis across the Blood-Brain Barrier Findings like these hint that future therapies might not only choose the right receptor to target but also nudge the cell’s internal routing toward completing the delivery rather than recycling the drug back into the bloodstream.
M Cells and Oral Vaccine Design
The transcytotic activity of M cells in the gut has drawn attention from vaccine developers. Because M cells naturally sample luminal contents and deliver them to immune tissue, they represent a built-in gateway for oral vaccines. If a vaccine particle can be engineered to target M cells specifically, it could be transcytosed directly to the Peyer’s patches beneath, where it would encounter the immune cells needed to mount a response.28PubMed Central. The Roles of Peyer’s Patches and Microfold Cells in the Gut Immune System: Relevance to Autoimmune Diseases This approach sidesteps one of the biggest problems with oral vaccines: most of the antigen gets destroyed by stomach acid or diluted in the gut before it can reach immune tissue. Targeted delivery to M cells concentrates the antigen where it needs to go.
The challenge is that M cells are relatively rare. They make up only a small fraction of the intestinal epithelium, so any targeting strategy has to be precise. Researchers have experimented with ligands that bind receptors enriched on M cell surfaces, decorating nanoparticles or microparticles with these ligands so they are preferentially taken up. The underlying biology of M cell transcytosis, rapid uptake from the lumen and efficient handoff to dendritic cells below, is well established. The engineering challenge is getting the vaccine to the right cell in the first place, and then ensuring the transcytosed antigen triggers a robust immune response rather than tolerance.
The dual nature of gut transcytosis, outward antibody secretion via pIgR and inward antigen sampling via M cells, creates a feedback loop that maintains gut immune balance. Disrupting either arm can have consequences. Reduced pIgR expression, for instance, has been linked to inflammatory bowel conditions, and altered M cell function has been implicated in the breakdown of oral tolerance. Both arms rely on transcytosis, but they serve opposing purposes: one sends defenders out, the other pulls intelligence in.